期刊文献+

杂交捕获法和PCR-RDB法检测妇女HPV感染的比较 被引量:3

Comparison between HC2 and PCR-RDB for detecting HPV infection in women
下载PDF
导出
摘要 目的探讨HC2法和PCR-RDB法检测妇女HPV感染的异同点。方法利用HC2法和PCR RDB法检测妇女生殖道HPV感染状况,然后进行比较。结果81.14%(400/493)的样本PCR-RDB法和HC2法检测结果一致,两法一致性检验Kappa值为0.63(95%CI,0.57~0.69)。在HC2法RLU/CO<1.00、1.00~9.99、10.00~99.99、100.00~999.99和≥1 000.00的样本中,PCRRDB法13种高危型HPV的检出率依次为1.60%(3/187)、29.85%(20/67)、69.88%(58/83)、86.52%(77/89)和91.04%(61/67),五组间比较,差异有统计学意义(X^2=289.3,P<0.01)。HC2法高危型HPV试剂可与HPV53、66、11、cp8304等基因型发生交叉反应。结论HC2法和PCR-RDB法具有较好的一致性,HC2法存在交叉反应现象,PCR-RDB法难以标准化。 Objective To compare hybrid capture-Ⅱ (HC2) to polymerase chain reaction (PCR)-reverse dot-blot(RDB) for detecting HPV infection in women. Methods HC2 method and PCR-RDB were applied to detecting human papillomaviral infection in female genital duct, and the test results were analyzed. Results Concordant results were found in 81.14% (400/493) samples (Kappa =0.63; 95% CI, 0. 57-0. 69). The high risk type HPV positive rate detected by PCR-RDB were 1.60% (3/187),29.85% (20/67), 69.88% (58/83), 86.52% (77/89) and 91.04% (61/67), respectively, when the HC2 RLU/CO of samples were〈1. 00, 1.00-9.99, 10.00-99.99, 100.00- 999.99 and ≥1 000.00. Statistical differences were found among the five groups (Х^2 = 289.3, P〈0.01). Cross reactions were found between HC2 high risk probe and HPV53, 66, 11, cp8304 and other genotypes. Conclusion There is good concordance between HC2 and PCR-RDB, though cross reaction exists in HC2. Relatively speaking, there are more influential factors for PCR-RDB.
出处 《国际检验医学杂志》 CAS 2009年第6期545-547,共3页 International Journal of Laboratory Medicine
关键词 人乳头瘤病毒16 人乳头瘤病毒18 聚合酶链反应 交叉反应 Human papillomavirus 16 Human papillomavirus 18 Polymerase chain reaction Cross reactions
  • 相关文献

参考文献12

  • 1Flores-Munguia R, Siegel E, Klimeeki WT, et al. Performance assessment of eight high-throughput PCR assays for load quantitation of oneogenie HPV gypes[J]. J Mol Diagn, 2004, 6 (2): 115-124.
  • 2Mayrand MH, Coutlee F, Hankins C, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analisys[J]. J Clin Microbil, 2000, (38):3388-3393.
  • 3Liaw KL, Hsing AW, Chen CJ, et al. Human papillomavirus and cervical neoplasia:a case-control study in Taiwan[J]. Int J Cancer, 1995, 62(5):565-571.
  • 4Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human paillomavirus infection causes most cervical intraepithelial neoplasia[J]. J Natl Cancer Inst, 1993, 85 (12) :958-964.
  • 5Walboomers JM, Jaeobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J].J Pathol, 1999, 189(1) :12-19.
  • 6Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med, 2003, 348(6):518-527.
  • 7肖克林,王丁,周克元.HC2法在宫颈癌筛查中的应用现状[J].国际检验医学杂志,2008,29(4):364-366. 被引量:7
  • 8Gravitt PE, Peyton CL, Apple RJ. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridizatio, reverse line blot detection method[J]. J Clin Microbiol, 1998, 36(10):3020-3027.
  • 9Soderlund-Strand A, Rymark P, Andersson P, et al. Comparison between the Hybrid capture Ⅱ test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia[J]. J Clin Microbiol, 2005, 43(7) :3260-3266.
  • 10Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies[J]. J Clin Microbiol, 1998, 36(11):3248-3254.

二级参考文献20

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2Hampl M. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines [J]. Minerva Med, 2007, 98(2): 121-130.
  • 3Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006 [J]. CA Cancer J Clin. 2006, 56(1): 11-25, quiz 49-50.
  • 4Guyot A, Karim S, Kyi MS, et al. Evaluation of adjunctive HPV testing by Hybrid Capture Ⅱ in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy [J]. BMC Infect Dis, 2003, 3: 23.
  • 5Poljak M, Brencic A, Seme K, et al. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer [J]. J Clin Microbiol, 1999, 37 (3) : 796-797.
  • 6Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples [J]. J Clin Microbiol, 2006, 44(6): 2141-2146.
  • 7Carozzi F, Bisanzi S, Sani C, et al. Agreement between the AM- PLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease[J]. J Clin Microbiol, 2007, 45(2): 364-369.
  • 8Lee KJ, Lee JK, Saw HS. Can human papillomavirus DNA testing substitute for cytology in the detection of high-grade cervical lesions [J]? Arch Pathol Lab Med, 2004, 128(3): 298-302.
  • 9Andersson S, Dillner L, Elfgren K, et al. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities [J]. Acta Obstet Gynecol Scand, 2005, 84(10): 996-1000.
  • 10Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral[J]. JAMA, 2002, 288(14): 1749-1757.

共引文献28

同被引文献35

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部